Charles S. Grob, M.D. is Director of the Division of Child and Adolescent Psychiatry at Harbor-UCLA Medical Center, and Professor of Psychiatry and Pediatrics at the UCLA School of Medicine. He did his undergraduate work at Oberlin College and Columbia University, and obtained a B.S. from Columbia in 1975. He received his M.D. from the State University of New York, Downstate Medical Center in 1979.
Prior to his appointment at UCLA, Grob held teaching and clinical positions at the University of California at Irvine, College of Medicine, and The Johns Hopkins University School of Medicine, Departments of Psychiatry and Pediatrics. He conducted the first U.S. government approved psychobiological research study of MDMA, and was the principal investigator of an international research project in the Brazilian Amazon studying the visionary plant brew, ayahuasca. The results of his completed investigation on the use of psilocybin to treat advanced-cancer patients with psilocybin will be published in the January, 2011 issue of the Archives of General Psychiatry.He is the editor of Hallucinogens: A Reader, published by Tarcher/Putnam in 2002, and the co-editor (with Roger Walsh) of Higher Wisdom: Eminent Elders Explore The Continuing Impact Of Psychedelics, published by SUNY Press (State University of New York Press) in 2005, and he has published numerous articles on psychedelics in medical and psychiatric journals and collected volumes. He is a founding member of the Heffter Research Institute, which is devoted to fostering and funding research on psychedelics.
- Key Collaborator “The Legacy of Transformation” 2002
This discussion reviews the history of psychiatric research with psychedelics from the 1950s to the present. Particular focus is applied to recent approved investigations with normal volunteers and with specific patient populations, including those with advanced-cancer anxiety, obsessive-compulsive disorder and chronic post-traumatic stress disorder. Implications of research conducted in the ...